Can we predict who will get dangerous side effects from a common brain cancer drug?

NCT ID NCT06546631

Recruiting now Knowledge-focused Sponsor: University College Cork Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at why some people with brain tumors (gliomas) develop low blood cell counts from the drug temozolomide, while others don't. Researchers will analyze genes, gut bacteria, and other factors in 55 patients to find clues. The goal is to help doctors predict and prevent this side effect in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: temozolomide
What this could lead to: If successful, this could help doctors predict which patients are at higher risk of severe blood side effects from temozolomide, allowing them to take steps to reduce that risk.
What could go wrong: This is a small, early-stage observational study (55 participants) that aims to identify predictors, not test a new treatment. It may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) glioblastoma glioma malignant glioma oligodendroglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Locations

Cork University Hospital
RECRUITING

Cork, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.